Maxygen Inc (MAXY1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
515 GALVESTON DRIVE REDWOOD CITY, CA 94063

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Maxygen, Inc. (Maxygen) is a biotechnology company focused on the development of its MAXY-G34 product candidate. MAXY-G34 is a pegylated, granulocyte colony stimulating factor (G-CSF), for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome (ARS). On May 16, 2011, Astellas Pharma Inc. (Astellas) acquired the Companys interests in Perseid Therapeutics LLC, the Companys former subsidiary, which included all of the Companys research and development operations. As a result of the transaction, the Company has reclassified the operating results of Perseid, as well as any related business activities, to discontinued operations. The Companys wholly owned subsidiaries include Maxygen Holdings (U.S.), Inc., Maxygen ApS and Maxygen Holdings, Inc., and its majority owned subsidiary, Maxygen Holdings LLC.

View SEC Filings from MAXY1 instead.

View recent insider trading info

Funds Holding MAXY1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MAXY1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BORKHOLDER JOHN GENERAL COUNSEL & SECRETARY

  • Officer
80,684 2013-08-13 0

SULAT JAMES R FORMER CEO & CFO

  • Officer
  • Director
No longer subject to file 2013-06-30 0

RINGOLD GORDON

  • Director
357,562 2012-06-06 0

MARIO ERNEST

  • Director
62,964 2012-06-06 0

LEE KENNETH B JR

  • Director
64,000 2012-06-06 0

LANGE LOUIS G

  • Director
60,000 2012-06-06 0

STEIN ISAAC

  • Director
635,904 2011-05-19 0

YONEHIRO GRANT SENIOR VICE PRESIDENT

  • Officer
No longer subject to file 2011-05-16 0

CONUS PARTNERS INC

ZACKS ANDREW

  • 10% Owner
No longer subject to file 2010-03-18 0

GLAXOSMITHKLINE PLC

  • 10% Owner
No longer subject to file 2009-12-30 0

GOLDSTEIN ELLIOT CHIEF OPERATING OFFICER

  • Officer
No longer subject to file 2009-10-30 0

BRISCOE LAWRENCE W SENIOR VICE PRESIDENT AND CFO

  • Officer
No longer subject to file 2009-09-30 0

HOWARD RUSSELL J CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
No longer subject to file 2009-09-30 0

VETTICADEN SANTOSH CHIEF MEDICAL OFFICER

  • Officer
0 2008-07-01 0

GREENWOOD MRC

  • Director
0 2008-05-30 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments